Carisma Therapeutics (CARM) Stock Forecast & Price Target

$0.86 0.00 (0.00%)

(As of 11/20/2024 ET)

Carisma Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Based on 3 Wall Street analysts who have issued ratings for Carisma Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 2 have given a buy rating, and 1 has given a strong buy rating for CARM.

Consensus Price Target

$7.00
711.69% Upside

According to the 3 analysts' twelve-month price targets for Carisma Therapeutics, the average price target is $7.00. The highest price target for CARM is $8.00, while the lowest price target for CARM is $6.00. The average price target represents a forecasted upside of 711.69% from the current price of $0.86.

Get the Latest News and Ratings for CARM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Carisma Therapeutics and its competitors.

CARM Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.00	$7.00	$8.00	$10.00
Forecasted Upside	711.69% Upside	614.29% Upside	607.96% Upside	287.60% Upside
Consensus Rating	Buy	Buy	Buy	Buy

My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

The Next SpaceX Pre-IPO

CARM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CARM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Carisma Therapeutics Stock vs. The Competition

Type	Carisma Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.33	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	711.69% Upside	26,931.47% Upside	9.83% Upside
News Sentiment Rating	Neutral News See Recent CARM News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/30/2024	EF Hutton Acquisition Co. I 1 of 5 stars	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00	+520.10%
4/11/2024	BTIG Research 2 of 5 stars		Initiated Coverage	Buy	$6.00	+214.14%
10/3/2023	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Quibria Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00	+133.64%
7/6/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$12.00	+34.98%
5/31/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$7.00	+40.28%
4/14/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$10.00	+222.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:00 AM ET.

CARM Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Carisma Therapeutics is $7.00, with a high forecast of $8.00 and a low forecast of $6.00.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CARM shares.
: According to analysts, Carisma Therapeutics's stock has a predicted upside of 711.69% based on their 12-month stock forecasts.
: Over the previous 90 days, Carisma Therapeutics's stock had 1 upgrade by analysts.
: Carisma Therapeutics has been rated by research analysts at EF Hutton Acquisition Co. I in the past 90 days.
: Analysts like Carisma Therapeutics more than other "medical" companies. The consensus rating for Carisma Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CARM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

This page (NASDAQ:CARM) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Stock Forecast & Price Target